The Darlington and Northallerton prospective asthma study: best function predicts mortality during the first 10 years  by Connolly, C.K. et al.
RESPIRATORY MEDICINE (1998) 92, 1274-1280 
The Darlington and Northallerton Prospective 
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C. K. CONNOLLY*, M. MAMUN+, S. M. ALCOCK* AND R. J. PRESCOTT* 
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Newcastle upon Tyne, ‘University of Edinburgh, U.K. 
The DarlingtonlNorthallerton prospective study of asthmatics referred to secondary care started in 1983, with 
review and new entry at 5-yr intervals. The principal outcome measures are: mortality (presented here), best function 
and therapeutic step. All adult asthmatics with 2 15% peak flow (PEF) reversibility to 2 200 1 min - i were included. 
Socio-demographic variables, PEF and spirometry were recorded prospectively. Best vital capacity (FVC) and PEF 
were assessed according to protocol. The mortality of the original cohort after 10 yr was expressed as standardized 
mortality ratio (SMR) against the local population, with history and pulmonary function at entry as explanatory 
variables. Ninety-five per cent follow-up was achieved in 628 subjects, with 173 deaths (29.1% of those traced). The 
excess death rate was nearly 50% (SMR 1.47, 95% CI 1.26-1.71) with 56% of deaths due to respiratory disease 
(expected 10%). After allowance for age and sex, there was a consistent inverse relationship between mortality and 
entry best FVC, increased risk of death 1.51 (95% CI 1.33-1.72) per 10% deficit of best FVC predicted. 
The risk of respiratory death was eight times greater, and of non-respiratory death three times greater, in the 
lowest compared with the highest quartile of best FVC. There were no interactions with smoking, but possible 
enhancement of the effect in the socially deprived. Best FVC was a particularly powerful predictor of mortality in 
subjects 465 years at entry, in whom 64% of the excess deaths occurred. Most of the excess in respiratory deaths was 
not due to acute severe asthma but to the development of chronic obstructive pulmonary disease (COPD), as defined 
functionally, irrespective of smoking habit which made no further contribution to mortality. 
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Introduction 
The long-term prognosis of asthma in adults is ill under- 
stood both in terms of mortality and morbidity. In an 
attempt to elucidate this, all subjects with asthma attend- 
ing hospital and private clinics in the Darlington and 
Northallerton Health Districts were entered into a long- 
term follow-up study in 1983 with further entry and review 
planned at 5-yr intervals. If asthma is irrespective of the 
development of chronic obstructive pulmonary disease 
(COPD), then there will be a spectrum of asthmatic subjects 
from those with completely reversible disease to those with 
severe secondary persistent obstruction. Similarly, there will 
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be a spectrum in the contribution of acute recently revers- 
ible obstruction to mortality. It would require a special 
study to determine the precise nature of all respiratory 
deaths and therefore we have categorized respiratory deaths 
into those whose death was immediately related to an acute 
severe deterioration and to others. Socio-demographic 
variables and pulmonary function were recorded at entry. 
The aims of this study were to follow mortality, change in 
best function, and treatment necessary to maintain optimal 
control, in the light of the socio-demographic variables and 
pulmonary function prospectively recorded at each of the 
5-yr intervals. 
From the outset, it was decided to treat the persistent and 
reversible components of airway obstruction as separate 
and potentially independent variables. The persistent com- 
ponent was assessed by best function, measured after 
bronchodilator on optimal therapy, and the reversible 
component expressed as the actual function recorded at the 
index visit, divided by best function (1,2). 
It was hoped to exclude patients with established severe 
COPD by the entry criteria: reversibility of peak expiratory 
flow (PEF) by at least 15%- 2 200 1 min - ‘. After excluding 
these subjects, the hypotheses are: first, that asthma is a risk 
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factor for the further development of COPD, as assessed by 
best function, and second, that the development of COPD, 
whether caused by asthma or not, is a risk factor for 
mortality in asthmatics. 
The relationships between history, pulmonary function 
and therapy at entry have been reported elsewhere (2-4). 
This paper presents outcome at 10 yr in terms of mortality, 
and examines the relevance of the entry variables. 
Methods 
SUBJECTS 
All subjects over 18 years of age, whose working diagnosis 
included asthma, attending for follow-up at one of the 
author’s (C.K.C.) clinics in the former Darlington and 
Northallerton Health Districts of the National Health 
Service and privately, were included. The diagnosis of 
asthma was confirmed by reversibility of PEF at least twice 
at any time after first referral by at least 15% to at least 
2001min-‘. 
HISTORY 
Social and demographic variables were recorded at entry as 
previously described (2,3). These included: atopic status, 
social class (Registrar General’s classification), smoking 
habit, amount smoked, presence of pets, children, central 
heating and site of household. Duration of asthma was 
measured from first onset, or from recurrence after a 
symptom-free interval of at least 5 yr. Childhood asthma 
was defined as the presence of intermittent lower respirat- 
ory symptoms during childhood in the absence of chronic 
sputum production suggestive of bronchiectasis. 
PULMONARY FUNCTION 
The following were recorded at entry. 
Actual function 
PEF and FEV, (Rolling Seal Spirometer, Vitalograph, 
Maidenhead) were measured at the reference visit and 
corrected according to breath temperature and pressure 
saturated (BTPS). 
Best funcfion 
Best PEF and vital capacity (maintained for 6 s) (FVC) 
were assessed during the period from January 1982 up to 
and including the first visit (review January 1992). Best 
function was accepted as the best recorded in the notes, 
subject to the following criteria (5). 
If > 80% predicted: after bronchodilator. 
If 70-80% predicted: on regular maintenance therapy 
(sodium cromoglycate, inhaled corticosteroids or low-dose 
oral steroids) with 4-hourly charting of PEF for 7 days. 
If ~70% predicted: after bronchodilator, following 2 30 mg 
prednisolone for 2 7 days, with stable peak flow for 248 h. 
These criteria were satisfied independently for PEF and 
FVC. If not, best function was immediately established 
using the above protocol. The reference values of Cotes (6) 
were used. 
Actual best function 
The ratio of actual function at attendance to best function 
established according to the above protocol was expressed 
as a percentage. 
FOLLOW-UP 
All subjects were seen, recalled or traced at 5-yr intervals. 
The second (10 yr) review was conducted between April 
1993 and March 1994. Patients who neither attended for 
appointment nor whose death had been recorded in the 
notes were traced through their general practitioner and the 
local Register of Deaths. If this was not successful, 
an approach was made to the Family Health Services 
Authority. A search was also made at the Central Registry. 
Classification of death 
Deaths were recorded as being due directly to asthma, other 
respiratory or non-respiratory cause, on the basis of case 
records or death certificates, and accepted as of unknown 
cause if neither were available. Death from asthma was 
defined as death due to sudden or rapid deterioration of 
recently reversible airway obstruction. This was confirmed 
from the clinical records or contact with the general prac- 
titioners. All other respiratory deaths which neither satis- 
fied this definition nor were due to carcinoma of the 
bronchus were classified as other respiratory deaths, the 
great majority of which were ascribed to bronchopneu- 
monia or COPD. Carcinoma of the bronchus was regarded 
as non-respiratory death, because we were primarily con- 
cerned with deaths that might be associated with morbidity 
due to the asthmatic process. The mortality figures for the 
Darlington Health District for the 3 yr period 1990-1992 
were used to calculate the expected mortality, using lo-year 
age bands. These expected mortality figures were then 
compared with the observed mortality to calculate the 
standardized mortality ratios (SMR). Approximately one- 
third of the patients were recruited in Northallerton, 
where the published district SMR is lower than for 
Darlington [SMR vs England and Wales: Darlington 1.24, 
Northallerton 0.92 (1991)]. 
STATISTICAL METHODS 
Confidence intervals for SMRs were calculated using the 
method described by Gardner and Altman (7). Univariate 
and multivariate analysis of factors influencing the prob- 
ability of death were based on linear logistic regression 
analysis, expressing pulmonary function absolutely or as 
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TABLE 1. Subjects 
Male Female 
n (%) 3 10 (49.4) 318 (50.6) 
Mean age (years) (SD) 51.5 (158) 51.9 (16.9) 
Mean duration (yr) (SD) 18.4 (16.4) 20.6 (15.9) 
Atopic (%) 181 (58) 156 (49) 
Current smokers (%) 62 (20) 36 (11) 
Ex-smokers (%) 145 (47) 95 (30) 
Non-smokers (%) 103 (33) 187 (59) 
Actual PEF (1 min- ‘) (SD) 3.53 (141) 285 (112) 
Best PEF (1 min- ‘) (SD) 432 (122) 353 (90) 
Actual FEV, (1) (SD) 2.33 (1.09) 1.82 (0.78) 
Best FVC (1) (SD) 4.04 (1.13) 2.91 (0.80) 
per cent predicted before and after logarithmic transforma- 
tion. The associations were further explored by expressing 
mortality as SMRs against the local population. Short-term 
outcome may be best in the third quartile of actual/best 
function (8) so this quartile is used as the reference value. 
Minor discrepancies in total numbers are due to occasional 
missing values. Analyses are always based on the maximum 
number of subjects available. 
ETHICS APPROVAL 
The study was approved by the Darlington and 
Northallerton Research Ethics Committees. 
Results 
GENERAL 
Six hundred and twenty-eight subjects were recruited (Table 
1). Median best function was approximately 80% predicted, 
whether assessed by vital capacity or peak flow and almost 
half (46.2%) had never smoked (8 33%, $? 59%). The social 
class distribution was similar to the population from which 
they were drawn, with approximately one-third each in 
social classes I-II, III, and IV-V. At entry, five subjects 
were being treated with oral steroids for a condition other 
than asthma. Of the remaining 623, 596 (95.7%) were 
maintained on treatment which was mutually agreed by 
patient and physician as being satisfactory. Of these, 136 
(22.8%) were on bronchodilators alone, 46 (7.7%) main- 
tained on cromoglycate, 291 (48.8%) on inhaled corticos- 
teroids and 123 (20.6%) on oral corticosteroids. Thirty-four 
(5.4%) subjects were lost to follow-up and 173 of the 
remainder (29.1%) had died. 
Table 2 summarizes the outcome for all subjects, non- 
smokers, those with good (>80%) best FVC at presenta- 
tion, and those who would not have reached their 65th 
birthday by the lo-yr review. The mortality was greater 
than anticipated in all the sub-groups. The SMR of all 
subjects was 1.47 (95% CI 1.26-1.71) [$1.52 (CI 1.24-1.85); 
9 1.45 (1.141.81)]. The expected proportion of respiratory 
deaths was approximately 10% (Darlington Health District 
1993) compared to the observed proportion of 56%, which 
included all respiratory deaths. The deaths from asthma 
represented a small fraction of the total, but of the deaths in 
those due to reach an age of not more than 65 years by 
review, nearly one-quarter were from asthma. 
ASSOCIATIONS WITH ENTRY VARIABLES 
Univariafe analysis 
The univariate associations of mortality with social, demo- 
graphic and functional variables are shown in Table 3 for 
all subjects and for non-smokers. These associations are 
similar if restricted to younger subjects, those with entry 
best FVC >80% or respiratory deaths. 
There is an apparent advantage in female gender in all 
subjects, and in male gender in non-smokers. This is 
entirely due to greater life expectancy in females, and the 
predominance of female gender amongst elderly non- 
smokers, the SMR being independent of gender. The odds 
ratio (OR) for actual PEF (1.32) was less than for best PEF 
TABLE 2. Outcome for all subjects, showing percentage distribution of mortality and survival in those 
traced. The results for non-smokers, subjects with normal function at entry and those aged ~65 years 
at review are also shown 
All 
Best FVC Aged ~65 
Non-smokers >80% at entry years at review 
All 628 290 492 320 
Traced (%) 594 (94.6%) 275 (94.8%) 463 (94.1%) 294 (91.9%) 
Alive (% traced) 421 (70.9%) 213 (77.5%) 366 (79.0%) 262 (89.1%) 
Dead: 
Asthma (% traced) 12 (2.0%) 8 (2.9%) 9 (1.9%) 7 (2.4%) 
Respiratory (% traced) 66 (11.1%) 19 (6.9%) 33 (7.1%) 10 (3.4%) 
Non-respiratory (% traced) 62 (10.4%) 25 (9.1%) 38 (8.2%) 11 (3.7%) 
Unknown (% traced) 33 (5.6%) 10 (3.6%) 17 (3.7%) 4 (1.4%) 
All (% traced) 173 (29.1%) 62 (22.5%) 97 (20.9%) 32 (10.9%) 
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FIG. 1. Standardized mortality ratio by age. The 95% 
confidence intervals are shown. 
(1.37), as was that for actual FEV, (1.32) compared with 
best FVC (1.59). Nevertheless, there were associations with 
actual/best function which were weaker, and in particular, 
the odds ratio for the chosen spirometric variable (actual 
FEV,/best FVC) was appreciably less than for best FEV, 
(Table 3). There were several interrelationships between the 
other independent variables, the principal confounding 
factor being age. The effects of these associations are 
demonstrated in the multivariate analysis. 
Multivaviate analysis 
The effects of the demographic, social and functional 
variables on IO-yr mortality were explored by stepwise 
logistic regression analysis on several models. In each, only 
age, sex and best vital capacity remained significant. After 
allowance for age and sex, for each 10% deficit in FVC, the 
increased odds of dying were 51%, OR 1.51 (CI 1.33-1.72). 
When expressed absolutely after allowance for age, sex and 
height, this amounted to 14% for each 100 ml decrement in 
best FVC (OR 1.14, CI 110-1.19). There was no significant 
difference between smokers and non-smokers. The odds 
ratios per 10% predicted were: non-smokers 1.45 (CI 1.20- 
l-78), smokers 1.60 (CI 1.46-1.7); and for each 100 ml: non- 
smokers 1.14 (CI 1.06-1.21), smokers 1.15 (CI 1.10-1.21). 
Although age and best FVC emerged as significant predic- 
tors of death, the odds ratios do not reveal how the effect 
compares with the general population. Fig. 1 examines the 
SMR relation to age and shows a progressive fall from 6.2 
below the age of 35 to 1.0 at over 75 years. Similarly Fig. 2 
shows that mortality is more than twice that of the general 
population when best FVC is less than 55% and non- 
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Standardized mortality ratio by best 
vital capacity (overall) 
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FIG. 2. Standardized mortality ratio by best vital 
capacity. The 95% confidence intervals are shown. 
significantly above average when greater than 115% pre- 
dicted. Those in the worst quartile of FVC were 5.5 (95% CI 
2.99-10.3) more likely to die than those in the best quartile, 
but the pattern varied with age. In those expected to reach 
65 years at review, the outlook was particularly bad in the 
fourth quartile (OR 8.1; CI 3.59-18.4). These patients were 
14.4 (CI 4.66-44.8) times more likely to die where best FVC 
was 65% as opposed to 85% predicted. In older subjects 
the principal disadvantage was in being outside the best 
quartile of FVC or having a vital capacity of ~105% 
predicted. 
After allowance for age and sex, the outcome in the first 
and second quartiles of actual/best FVC was marginally 
worse than in the third. First quartile OR 1.80; (CI 0.99- 
3.23): second quartile OR 1.98; (CI 1.01-3.66): fourth 
quartile OR 1’ 18; (CI 06-2,33), suggesting a small adverse 
effect of poor control. 
Social class was a predictor of poor outcome. The odds 
ratio (social classes 1 and 2) were 1.10 (CI 0.66-1.83) for 
social class 3 and 1.82 (CI 1.69-3.04), for social classes 4 
and 5. These differences disappeared after allowance for 
best vital capacity. There was little apparent disadvantage 
in current smoking OR 1.40; (CI 0.8-2.41 P=O.22), even in 
heavy smokers, where there were significantly less deaths 
than expected. 
CAUSE OF DEATH AND BEST VITAL 
CAPACITY 
Table 4 shows the relative mortality comparing the best 
quartile of FVC with the others. There was no relationship 
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TABLE 3. Univariate analysis of the relative risk of death in 
all subjects and non-smokers 
All (CI) Non-smokers (CI) 
Iz 
Gender 
Male 
Female 
Age (decades) 
Duration (decades) 
Atopic 
Childhood asthma 
Smoker 
Current 
Ex- 
Non- 
Amount smoked 
(10 pack-years) 
Social class 
I-III 
IV-V 
*Best PEF 
tAct./best PEF 
Best FVC 
“Act.FEV,/ 
best FVC 
594 
1.47 (1.03-2.10) 
1.00 
2.44 (2.03-2.93) 
1.14 (1.03-1.27) 
0.68 (0.47-0.99) 
0.54 (0.37-0.80) 
1.69 (1.01-2.83) 
1.90 (1.28-2.81) 
1.00 
1.19 (1.10-1.30) 
1.00 
1.78 (1.23-2.59) 
1.37 (1.25-1.51) 
1.25 (1.13-1.39) 
1.59 (1.41-1.80) 
1.16 (1.06-1.27) 
275 
0.76 (0.42-1.40) 
1 .oo 
3.10 (2.234.31) 
1.19 (1.00-1.42) 
0.43 (0.24078) 
0.33 (0.17-0.62) 
1.00 
2.34 (1.29-4.23) 
1.24 (1.07-1.44) 
1.38 (1.16-1.63) 
1.45 (1.21-1.74) 
1.01 (O+%-1.16) 
*Per deficit of 10% predicted. 
SPer 10% deficit. 
between deaths attributed directly to asthma and best FVC 
at entry. On the other hand, there was a significant risk of 
other respiratory death with reduced vital capacity, which 
was apparent throughout the whole range. The association 
between non-respiratory deaths and reduced vital capacity 
was principally in the worst quartile. 
Discussion 
The primary aim of the Darlington and Northallerton 
Asthma Study is to follow mortality, changes in pulmonary 
function, and therapy required to maintain optimal func- 
tion, in a group of patients sufficiently severe to be referred 
to secondary care. This is a clinical rather than an epi- 
demiological study and, therefore, has the potential 
disadvantage of an ill-defined and selected population. 
Nevertheless, it is likely that a high proportion of eligible 
subjects from the geographical area concerned is included. 
The boundaries are well defined and there was only one 
respiratory physician in the area during the period of the 
study. It has the advantage that subjects so referred are 
likely to be more severely affected, show greater changes 
and hence make the assessment of risk factors easier. On 
the other hand, the distribution of these risk factors and 
their effect might be different in less severely affected 
subjects managed in general practice or recruited in 
epidemiological studies, who might fare better (9). 
Previously published studies (10) have shown that a 
history of COPD is associated with poor outcome in 
asthma, but this is the first time that best function and 
actual/best function at entry have been considered indepen- 
dently as possible risk factors for mortality. On multivariate 
analysis, only one measure of best function (FVC) remained 
in the model and in the 5-yr period after 1988, when best 
FEV, was also assessed, the closest fit was with best FEV, 
(11). Although the fit is not as good with best PEF, the 
conclusions are the same. 
The weaker univariate relationship between poor actual/ 
best function and mortality was, nevertheless, of the same 
order, but did not remain in the model on multivariate 
analysis. Confounding factors which might explain this 
include the cross-sectional association of low actual/best 
function with greater age and lower social class (3). 
Although the relationship between actual/best and best 
function is weak (1 l), both actual/best and best function 
were lower in patients maintained on oral corticosteroids at 
entry (4), who might have a worse prognosis. The relation- 
ship between actual/best function and symptoms in subjects 
in this study is generally U-shaped, the group of patients 
with no demonstrable reversible disease at attendance hav- 
ing more symptoms than those with minimal reversibility 
(8). The symptomatic patients with little reversibility, often 
on long-acting bronchodilator, might have a poor prog- 
nosis and so reduce the scope for showing an association 
between good control at attendance and poor outcome. 
These results are compatible with a weak relationship 
between actual/best peak flow at entry and mortality, which 
is partially confounded by a group of poor prognosis 
subjects with limited reversibility at entry, possibly further 
reduced by long-acting bronchodilator. This interpretation 
would support the findings of Brown et al., who did find a 
relationship between unsatisfactory management and poor 
long-term outcome (13). Furthermore, a single reading of 
actual/best function is a crude measurement of control, and 
a record of diurnal variation might have proved a more 
powerful tool, although it is unlikely that the effect of 
unsatisfactorily controlled reversible airway obstruction 
exceeds that of entry best function. 
We have shown that there is a close association between 
respiratory mortality and poor best function. Although the 
association with non-respiratory mortality was not as great, 
it was both significant and relevant. This is in agreement 
with population studies, which have shown that reduced 
FEV, is associated with increased non-respiratory mortality 
(14,15), particularly from coronary heart disease and stroke 
(16,17). This is not entirely a smoking effect, as it is also 
seen in lifelong non-smokers (18). Some epidemilogical 
studies have suggested that reversible airway obstruction is 
a good prognostic factor (19). However, the use of actual, 
rather than best function, in all previous studies would 
explain this paradox if, indeed, best function is the principal 
explanatory variable. The approach in separating the per- 
sistent and potentially reversible components has the 
advantage not only of looking at factors that might have 
different aetiology and prognostic factors, but also in 
ensuring that one component does not suffer from the 
variability inherent in single measurements of pulmonary 
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TABLE 4. The relative cause-specific and overall risk of death by quartiles of best vital capacity 
FVC 
quartile 
Interquartile Unknown 
value Asthma Other respiratory Non-respiratory cause All 
(% pred) ratio (n) ratio (n) ratio (n) ratio (n) ratio (72) 
1 1.3 (4) 8.3 (33) 2.8 (25) 2.1 (16) 3.5 (78) 
83.7 
96.3 
109.1 
2 0.7 (2) 3.5 (14) 1.6 (14) 0.7 (4) 1.5 (34) 
3 1.0 (3) 2.5 (10) 1.1 (10) 0.7 (4) 1.2 (27) 
4 1.0 (3) 1.0 (4) 1.0 (9) 1.0 (6) 1.0 (22) 
All WI (61) (58) (30) (161) 
P (exact trend test) 0.90 ~0~0001 0.002 0.02 <0~0001 
function. It may prove to be of particular importance in 
the actuarial assessment of asthmatics for insurance and 
medico-legal purposes. Whilst the protocol for best func- 
tion used here has not been fully validated, it is the only 
published one and has been shown to be the denominator 
which produces consistent actual/best function across 
different regimens (5). 
The classification of respiratory deaths is less than ideal. 
We are confident that we had sufficient information to 
make a diagnosis of death from acute severe asthma when 
this had occurred, but it proved impossible to assess the 
contribution of reversible wheeze to the deaths of those who 
had symptoms associated with chronic obstruction. There 
seemed no consistent difference between those recorded as 
dying from bronchopneumonia and various forms of 
obstructive pulmonary disease. It would have required a 
special study, with possibly a post-mortem on all occasions, 
to assess the contribution of the currently reversible com- 
ponent to these deaths. We have therefore classified them 
all as other respiratory deaths. However, we have shown 
that the increased risk of these respiratory deaths is associ- 
ated with differences in best function within, as well as 
below the normal range. Two-thirds of the excess deaths 
were in patients of age less than 65 years. Although in these 
younger subjects the hazard was principally in the worst 
quartile of function, we are confident that, as subjects get 
older, relatively minor degrees of COPD may substantially 
increase the risk of mortality in asthmatics. Possible mecha- 
nisms include reduction of ability to survive a relatively 
modest increase in the acute reversible component of their 
obstruction, or during infective episodes, heightened risk of 
bronchopneumonia. 
made for age. In our study, asthma deaths did make a 
major contribution to the mortality of the younger subjects. 
The incidence was compatible with the rate of 0.5-0.9 per 
100 000 per year for subjects aged 5-34 years in the U.K. as 
a whole (22). Even in the younger subjects, concentrating 
on deaths directly attributable to asthma will underestimate 
the effect of the development of COPD as the strength of 
the relationship between all deaths and poor best function is 
inversely related to age. The analysis of changes in vital 
capacity in the survivors of this cohort would suggest a 
linear decline, little influenced by the previous determinants 
of entry best function. Nevertheless, reduction in parental 
smoking, which compromises respiratory development in 
susceptible subjects (23), or early intervention in children 
with frank asthma (24), must improve outcome in later life 
by ensuring a higher starting value before the adult decline 
in pulmonary function. There was no additional adverse 
interaction with cigarette smoking, with the whole of its 
effect being explained by reduction in best function. Simi- 
larly there was no interaction between pulmonary function 
and social class. Although this indicates that in the lower 
social classes there is no additional disadvantage in having 
poor pulmonary function, it is compatible with the 
interpretation that the difference in outcome between the 
socially deprived and the relevantly affluent is mediated 
through poor best function. 
There are early indications that it might be possible to 
conserve pulmonary function by the early introduction of 
corticosteroids (25). 
It is therefore particularly important that the socially 
deprived do have the benefit of early appropriate manage- 
ment of their asthma. 
The overall mortality was less than that reported by The results presented here suggest that maintenance of 
Markowe et al. [SMR 1.6 (CI 1.3-2.0)] (8), but if allowance best function should be a principal aim of the management 
is made for the relative youth of the subjects studied, similar of asthma. Nevertheless, these results do not preclude the 
to that reported by Lange et al. [SMR male 1.5 (CI 1.2-1.9) use of increased bronchodilator rather than inhaled corti- 
female 1.7 (CI 1.3-2.2)] (20) and Ulrik [SMR 1.94 (CI costeroids to achieve better control of symptoms (26) 
1.17-2.42)] (21). Although there were relatively few deaths provided that the anti-inflammatory medication is given in 
directly attributable to asthma in our study, the findings are sufficient dosages to maintain after-bronchodilator function 
again compatible with those of Ulrik (21) if allowance is at its highest possible level. 
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